The Script: California Board of Pharmacy newsletter summaries

May 2026

The Board’s first regular issue after the AB 1503 special edition, and it spends most of its length on implementation. The nonresident policy statement and the new self-assessment form are the two items owners should read closely.

• A policy statement on nonresident pharmacies. The Board approved it at the April 2026 meeting to explain what AB 1503 changed for pharmacies shipping into California. It walks through the obligations that now apply, including the duty not to obstruct a patient’s access to a legally prescribed drug under Business and Professions Code section 733, the quality assurance program required by section 4125 and California Code of Regulations title 16 section 1711, and the operational standards and security requirements in section 1714.
• A new community pharmacy and hospital outpatient self-assessment form. AB 1503 pulled the self-assessment requirement out of the regulations and put it in statute at Business and Professions Code section 4040.6, and the Board approved a new form to match. If you are working off an older form, replace it.
• The inspection process, explained in the Board’s own words. What an inspector leaves behind after a visit: an inspection report signed by the inspector, the pharmacist or designated representative and the owner if present, a receipt for any records taken, and a written notice where the inspector believes there is a possible violation. The article also states that the licensee gets an opportunity to submit additional information for the investigation file.
• Access control and electronic badge systems. Prompted by an actual investigation. A hospital pharmacy used badges that recorded entry but did not distinguish pharmacists from technicians. The article restates the rule that the dispensing area must be secured and separated by a floor to ceiling barrier, and that access records, while not required, are treated as a best practice at inspection.
• Corresponding responsibility when dispensing buprenorphine. The Board’s position is that because buprenorphine is usually prescribed for opioid use disorder, therapeutic intent should be part of the pharmacist’s corresponding responsibility analysis rather than a reason to refuse.
• CAMER registration has to be renewed. Community pharmacies report medication errors through the California Medication Error Reporting system, administered for the Board by the Institute for Safe Medication Practices. Errors occurring on or after September 1, 2025 are reportable, and the ISMP registration carries a fee.
• What counts as non-sterile compounding. A Compounding Corner piece running through USP chapter 795 with concrete examples: reconstituting common oral antibiotic suspensions, repackaging manufactured products, tablet splitting, and preparing a single dose that will be administered within four hours.
• Advanced pharmacist practitioner authority. The title changed from advanced practice pharmacist under AB 1503, and the article restates the authority under section 4052.6, including patient assessment, referrals, and initiating, adjusting or discontinuing drug therapy with notice to the diagnosing prescriber.
• Two licensure exemptions worth knowing. Prescriptions from providers employed by a tribal health program and licensed in another state may be filled in California, and the federal Servicemembers Civil Relief Act lets a servicemember or spouse licensed elsewhere practice here, with a state registration process under section 115.10.
• Scam calls are still running. Callers spoofing the Board’s own phone number, claiming to be investigators, confirming license numbers and NPIs, and referencing controlled substances found in a vehicle. The Board does not operate this way.

Read the May 2026 issue on the Board’s website → (PDF, 36 pages)

Special edition: AB 1503

January 2026

A special edition devoted to AB 1503 (Berman, Chapter 196, Statutes of 2025), the Board’s sunset measure, signed October 1, 2025 and extending the Board through January 1, 2030. This is the single most consequential issue in the last four years for anyone who owns or operates a pharmacy, and it deserves a careful read rather than a skim.

• Pharmacist practice moves to a standard of care model. Sections 4050, 4051 and 4052 were amended to strip prescriptive requirements from specified services in favor of an accepted standard of care. The statute also says a pharmacist should not provide a service where they lack the training, information or expertise, where doing so would put the patient at risk, or where pharmacist staffing is insufficient to support comprehensive patient care.
• Nonresident pharmacies need a California-licensed pharmacist in charge. Effective July 1, 2026, a nonresident pharmacy applying for or renewing a license must designate a pharmacist in charge for its California operations, report that person’s name, California license number and effective date within 90 days of appointment, report any later change within 90 days, and complete the Board’s PIC training. Medication error reporting for nonresident pharmacies is now limited to prescriptions dispensed to California residents.
• Mail order pharmacies face six-figure fines. New section 4317.6 lets the Board cite and fine a mail order pharmacy up to $100,000, mirroring the authority it already had over chain community pharmacies. A mail order pharmacy is defined as a nonresident pharmacy that ships to patients by mail or similar delivery.
• The self-assessment process is now in statute. New sections 4040.6 and 4102 define the process and set the timing: before July 1 of every odd-numbered year, within 30 days after a new license issues, and within 30 days after a change in pharmacist in charge or designated representative in charge.
• The pharmacist in charge decides staffing. Section 4113 now says the PIC makes staffing decisions sufficient to prevent fatigue, distraction or other conditions that interfere with competent practice. The Board’s president called this out separately as one of the provisions it fought for.
• The prescriber ownership bar loosened, with conditions. Section 4111 was amended to allow pharmacy ownership where the applicant shares a community or other financial interest with a prescriber, provided the prescriber disavows any direct or indirect interest and the pharmacy is transmuted into separate property. Applications and instructions have been updated, and the Board points questions to phystatus@dca.ca.gov.
• Records can be digitized, with an audit trail. Sections 4081 and 4105 now require policies and procedures to be readily retrievable, require electronic records to carry an audit trail of revisions for three years, and permit paper records to be converted and kept in a non-editable digital format. The Board may require certification that digitized records were not altered, and it warns that DEA requirements still apply.
• Technician duties and ratios changed. Section 4115 was amended to clarify what a specially trained technician may do and to authorize compounding or vaccine administration outside a licensed pharmacy under a pharmacist’s direct supervision. The pharmacist to technician ratio changed as well.
• A fee waiver for medically underserved areas. Section 4400 now lets the Board waive application and renewal fees for a pharmacy providing in-person care in a medically underserved area, defined as an area with no physical pharmacy providing in-person pharmacist care within 50 road miles.
• Hospital pharmacies and high-risk patients. Section 4118.5 now requires an accurate medication profile for each high-risk patient on discharge as well as on admission, at hospitals with more than 100 beds. The hospital sets the criteria for who is high risk, and trained technicians or interns may do the work under a quality assurance program.
• Also in this issue. A pharmacy technician advisory committee, the title change to advanced pharmacist practitioner, statutory definitions of pharmacist and technician trainee, a restoration pathway for retired licenses within three years, emergency refill provisions, and continued authority for COVID-19 oral therapeutics.

Read the January 2026 issue on the Board’s website → (PDF, 14 pages)

November 2025

The annual new-laws issue, plus the two enforcement data sets that are the most useful pages the Board publishes all year: what inspectors actually cited, and what those citations cost.

• New laws effective January 1, 2026. The rundown covers AB 82 on legally protected health care activity, AB 260 on sexual and reproductive health care including mifepristone labeling and coverage, AB 309 on hypodermic needles and syringes, AB 447 on emergency room patient prescriptions, AB 489 barring AI systems from implying a licensed human is providing care, AB 1152 removing hCG from Schedule III, SB 40 on insulin, SB 41 on pharmacy benefits, SB 306 on prior authorizations, SB 470 on teleconferenced meetings, SB 497 on legally protected health care activity, and SB 568 on epinephrine at schools.
• Top inspection findings, split by chain and non-chain. For chain pharmacies the leading corrections were operational standards and security (CCR 1714), license display (BPC 4058), pharmacists administering vaccines (CCR 1746.4), the PIC self-assessment (CCR 1715), and duty to consult (CCR 1707.2). For non-chain pharmacies the list led with controlled substance inventory reconciliation (CCR 1715.65), duty to consult, operational standards and security, patient-centered labels (CCR 1707.5), and federal inventory requirements. The Board’s stated goal is to inspect every pharmacy every four years.
• Citations issued in fiscal year 2024-2025. The top ten by violation for chain and non-chain pharmacies, plus the citations issued under the elevated authority in section 4317.5, which included quotas set by a chain pharmacy under BPC 4113.7 and obstruction of dispensing under BPC 733.
• Immunization authority shifts to standard of care. Under AB 1503, independent pharmacist initiation and administration of vaccines for patients three and older moved to a standard of care model effective January 1, 2026. The Board encouraged pharmacists to start the transition before the date.
• Vaccine consent forms and wrong-vaccine complaints. The Board is still receiving complaints about consent forms not being reviewed and consultation not being given, with patients receiving the wrong vaccine as a result. It asks that the person administering confirm identity and the vaccine requested using open-ended questions, and points to CCR 1746.4 for what follows administration.
• Medication error reporting went live. Errors occurring on or after September 1, 2025 must be reported to the CAMER system under BPC 4113.1, and an API is available for pharmacies that want to submit directly from their own systems.
• Technology does not carry the pharmacist’s judgment. An article making the point that e-prescribing, automated dispensing and robotics support the workflow but do not replace pharmacist oversight at any stage.
• Also in this issue. Regulations that took effect in 2025 including the reduced technician renewal fee (CCR 1749(c)), the PIC training webinar, standing orders for albuterol and epinephrine in schools, the online portal for reporting a drug theft or loss, and a CAMER case study on a vancomycin kit dispensed without reconstitution.

Read the November 2025 issue on the Board’s website → (PDF, 37 pages)

May 2025

A sunset-review issue. The Board had just finished its 2024 review, and the practical content is about access to medication and about reporting obligations.

• Are you obstructing a patient’s access to a prescription. A direct piece on Business and Professions Code section 733 and the Notice to Consumers poster, which tells patients the pharmacy must provide any legally prescribed medicine or device unless they cannot pay, the pharmacist determines it would be unlawful, or it would potentially harm the patient. If a drug is not on hand, the pharmacy is expected to work with the patient to get it in a timely way.
• A new portal for reporting drug theft and loss. The Board launched an online portal for controlled substance theft or loss reports under CCR 1715.6. Using it is not mandatory, but it forces the report to carry everything the regulation requires.
• Wholesaler thresholds and what a pharmacy can do about them. The Enforcement Committee heard from the Healthcare Distribution Alliance and Cardinal Health on how distributor thresholds are set and what a threshold event is. This is the issue behind a lot of patient complaints about not being able to fill controlled substance prescriptions.
• SB 339 went from emergency regulation to permanent. Pharmacists may furnish up to a 90-day course of HIV pre-exposure prophylaxis, and beyond 90 days where specified conditions are met.
• Sunset review and 32 issues. The final report went to the legislative oversight committees on January 6, 2025, and the Board’s president, executive officer and a licensee member testified on March 11. The committees’ background paper raised 32 issues, which is where much of AB 1503 came from.
• Self-assessment forms to be updated annually. The Board said it hoped to start updating the forms yearly, or as laws change, beginning in 2026. Worth checking the form version before you certify one.
• Also in this issue. A CURES fee increase, five free training webinars, the continuing education requirement, the voluntary $25 renewal contribution to the state loan repayment program for practice in underserved areas, the tribal health program licensure exemption, and a recruiting piece on becoming a Board inspector.

Read the May 2025 issue on the Board’s website → (PDF, 28 pages)

December 2024

The most useful enforcement issue of the period. It publishes not just the common violations but the number of citations and the average fine for each, which is as close as the Board comes to telling you what a given mistake costs.

• Citation counts and average fines. Under section 4317.5(a): failing to notify the Board about the pharmacist in charge (BPC 4113), 62 violations averaging $4,777; medication error (CCR 1716), 32 averaging $8,621; operating more than 30 days without a PIC (BPC 4305), 21 averaging $6,562; duty to consult (CCR 1707.2), 19 averaging $5,000; unprofessional conduct (BPC 4301), 12 averaging $8,438; pharmacy staffing (CCR 1714.3), 9 averaging $7,083; disclosure of medical information, 8 averaging $8,250; quality assurance (CCR 1711), 8 averaging $5,000.
• Top violation notices on routine inspections. Operational standards and security (CCR 1714), controlled substance inventory reconciliation (CCR 1715.65), the PIC self-assessment (CCR 1715), technician tasks, ratios and supervision (BPC 4115), voiding of license (BPC 4312), duty to consult, unauthorized disclosure of prescription information (CCR 1764), compounding limitations (CCR 1735.2), and patient-centered labels (CCR 1707.5).
• Wholesaler thresholds, in more detail. The article confirms that DEA plays no role in setting distributor thresholds, describes Cardinal Health’s model-based approach to orders of unusual size, frequency or pattern, and explains that a threshold is a ceiling above which the distributor will not ship in a given period.
• ADDS quality assurance reporting. What an automated drug delivery system is under BPC 4017.3, where these devices sit, and what data has to be submitted for quality assurance reporting.
• Online renewal and a fee change. From January 1, 2025, eligible personal licenses renew online, and the fee schedule changed on the same date, including a decrease for pharmacy technicians.
• Emergency contraception access. Following a Board presentation on research findings, an article on gaps in awareness of pharmacy law and FDA action on levonorgestrel and ulipristal acetate.
• HIV PrEP authority expanded. SB 339 and the emergency regulation effective August 14, 2024, moving pharmacists from a 30-day to a 90-day course and beyond under conditions.
• Also in this issue. Two public apology letters from pharmacists on probation over mishandled flu vaccine, veterinarian prescriptions and the DEA and NPI question, the Notice to Consumers poster replacing the older Ask Your Pharmacist notice, more scam calls, and the tribal health program exemption.

Read the December 2024 issue on the Board’s website → (PDF, 45 pages)

May 2024

A compliance-deadline issue. Several obligations that started in January 2024 get their first plain-language explanation here, and one of them changes who can demand your records.

• The Medical Board can now demand pharmacy records on the Board of Pharmacy’s timeline. Under SB 815, from January 1, 2024, Board of Pharmacy licensees must produce records requested by the Medical Board of California within the same timeframe that applies to a Board of Pharmacy request. Easy to miss, and it changes how a Medical Board letter should be handled.
• A new continuing education requirement. Effective January 1, 2024, pharmacists and technicians must complete at least one hour of a cultural competency course in the two years before any renewal, per BPC sections 4231 and 4202.
• Medicare beneficiaries at the Medi-Cal price. A reminder that under BPC 4425, going back to SB 393 in 1999, pharmacies that participate in Medi-Cal must charge Medicare beneficiaries no more than the Medi-Cal rate plus a small processing fee.
• CURES reporting format changed. From August 1, 2024, dispensations had to be reported in ASAP version 4.2B. Data in the older 4.1 format stopped being accepted.
• Payers must cover pharmacist services. AB 317, signed in October 2023, requires health care service plans and specified disability insurers that cover a service within a pharmacist’s scope to pay for it when performed at an in-network or out-of-network pharmacy.
• Protected reproductive and gender-affirming services. The Legislature has declared pharmacists to be health care providers whose provision of reproductive health care and gender-affirming care is a legally protected activity, under SB 345.
• Name and gender change confidentiality. SB 372 and BPC 27.5 let a licensee notify the Board of a name or gender change and request that the previous information be kept confidential on public-facing records.
• Also in this issue. The statewide epinephrine standing order for schools, new regulations approved at CCR 1706.6 and 1707.6, COVID-19 oral therapeutics extended to January 1, 2025, digital signatures accepted under Government Code 16.5, a medication error case involving two doses in one container, and mobile pharmacy units in San Diego.

Read the May 2024 issue on the Board’s website → (PDF, 39 pages)

Special edition: AB 1286

March 2024

A special edition on AB 1286 (Haney, Chapter 470, Statutes of 2023), which the Board calls a first in the nation patient safety measure. It took effect January 1, 2024 and it is the origin of mandatory medication error reporting, the chain staffing rule, and the duty to escalate unsafe conditions.

• Mandatory medication error reporting. Before 2024 pharmacies generally did not have to report medication errors. AB 1286 requires a community pharmacy to report all medication errors to a Board-approved entity, with a limited exemption for some outpatient hospital pharmacies under BPC 4113.1(e). The Board explained it would contract a vendor first and announce an enforcement date by subscriber alert.
• Minimum staffing for chain community pharmacies. A chain community pharmacy must be staffed at all times a pharmacist is on duty, which replaced the older and vaguer requirement that someone be made available to assist.
• The duty to report unsafe conditions immediately. From January 1, 2024, the pharmacist in charge or the pharmacist on duty must immediately notify store management of any condition presenting an immediate risk of death, illness or irreparable harm to patients, personnel or pharmacy staff, under BPC 4113(d). This is the provision behind the notice the Board later published for posting in pharmacies.
• Expanded technician duties. Qualified technicians may prepare and administer influenza and COVID-19 vaccines by injection or intranasally, prepare and administer epinephrine, collect specimens for CLIA-waived tests, receive prescription transfers, and accept prescription clarifications, all under specified conditions.
• Surgical clinic changes. A consulting pharmacist must complete a self-assessment before July 1 of every odd-numbered year, replacing the old quarterly written certification, and renewal requirements changed.
• An FAQ the Board wrote for licensees. The back half of the issue is a question and answer set on who must report, what counts as a reportable error, staffing, unsafe conditions, technician duties and the surgical clinic form. It is still the clearest short explanation of AB 1286 the Board has published.

Read the March 2024 issue on the Board’s website → (PDF, 13 pages)

October 2023

The issue where AB 1286 was announced as signed, paired with a heavy dose of enforcement detail and two articles about who is allowed to talk to the patient.

• Medication errors involving automated systems must be reported. Errors related to an automated drug delivery system are reportable, and the quality assurance review goes to the Board at the time of the facility’s annual license renewal. The article lists what the report has to contain, starting with the name and license of the pharmacy operating the device.
• A technician cannot start the immunization. The Board had received complaints, and seen practices, where non-pharmacist staff initiated the vaccination process. In one case a patient who came in for TDaP received a COVID-19 vaccine after a clerk noted the vaccine type on the consent form.
• A technician cannot ask whether the patient wants a consultation. Published under the heading that it is against the law. The offer of consultation and the consultation itself belong to the pharmacist.
• Inspection results for fiscal year 2022-2023. Outcomes broken out by inspection type, including complaint-driven and probation visits, with counts of pharmacies receiving corrections and violation notices, and the most common violations behind them.
• What inspectors look for. A companion article listing the documents an inspector asks to see, including the self-assessment, CURES reporting, policies and procedures, the quality assurance policy and medication error reports, along with the physical items they check such as the will-call area, shelving, expired stock and cleanliness.
• Higher fines for repeat violations. A reminder of the elevated fine authority for repeated violations, which the Board has since used.
• DEA’s final rule on transferring electronic controlled substance prescriptions. Schedule II through V electronic prescriptions may be transferred between pharmacies for initial filling, with the federal requirements clarified.
• Compounding standards moved. With the November 1, 2023 compendial date for the revised USP chapters 795 and 797, the Board approved an updated policy statement on the transition period.
• Also in this issue. The compounding self-assessment timing under CCR 1735.2, digital signatures, notifying the Board within 30 days when you stop being the PIC, drug take-back notification, a scam that cost one pharmacist $27,000, and the tribal health program exemption.

Read the October 2023 issue on the Board’s website → (PDF, 34 pages)

January 2023

A short issue. The new-laws roundup is the substance, and the rest is the tail end of the pandemic waivers.

• AB 852 reworked the e-prescribing rules. Pharmacies, pharmacists and prescribers may decline an electronic prescription submitted through software that does not meet the requirements, more exemptions were created, and a prescriber claiming an exemption must register annually with the Board. The Board built an online registry of exempt prescribers and a separate registry for verifying a claimed exemption.
• AB 2914 added the cultural competency CE requirement. Effective January 1, 2024, one hour in the two years before the application period, for both pharmacists and technicians, with renewal blocked without it.
• SB 872 authorized mobile pharmacy units. A county, a city and county, or two specified hospital authorities may operate a mobile unit as an extension of an existing pharmacy license, dispensing everything except controlled substances, with notice to the Board 30 days before starting and 30 days before stopping.
• COVID-19 waivers ran 90 days past the emergency. The state of emergency ended February 28, 2023, and the Board’s waivers under BPC 4062 continued for 90 days after that.
• SB 212 and sharps waste. The statewide stewardship program for pharmaceutical and home-generated sharps waste requires retail pharmacies to make a reasonable effort to serve as authorized collectors.
• Also in this issue. USP’s publication of the revised chapters 795 and 797, online renewal with a credit card for hypodermic needle and syringe and other listed permits, the FDA’s Compounding Quality Center of Excellence, and the Pharmacist Well-Being Index.

Read the January 2023 issue on the Board’s website → (PDF, 20 pages)

August 2022

A regulations issue. Seven new or amended regulations cleared the Office of Administrative Law, several of which still shape how the Board inspects a pharmacy today.

• Ownership, management and control (CCR 1709). Amended to make the ownership disclosure standards specific, including ownership held through trusts. Effective April 1, 2022. This is the regulation behind most of the disclosure work in a pharmacy acquisition or a change of ownership filing.
• Inventory reconciliation of controlled substances (CCR 1715.65). Clarified what an inventory reconciliation is, defined inventory activities, named four non-Schedule II drugs that must be inventoried at least every 12 months, required the people who did the count and prepared the report to be identified, and required a signature or an accepted electronic equivalent. Effective January 1, 2023.
• Temporary closure notice (CCR 1708.1). A permit holder other than a correctional pharmacy must notify the Board of any temporary closure longer than three consecutive days. Effective October 1, 2022.
• Automatic refill programs (CCR 1717.5). A new regulation setting the parameters for pharmacies that offer auto-refill. Effective July 1, 2022.
• Two reporting changes that cut paperwork. Drug loss reporting (CCR 1715.6) was aligned more closely with the federal requirement, and vaccine administration no longer has to be reported to the patient’s primary care provider within 14 days unless the patient asks (CCR 1746.4). An email address must now be kept current with the Board (CCR 1704).
• Quotas are prohibited, and here is how to report one. BPC 4113.7 bars a chain community pharmacy from setting a fixed number or formula for prescriptions filled, services rendered, programs offered or revenue obtained, and the article explains how to file a complaint.
• Most common citations, fiscal year 2021-2022. For pharmacists: medication error (CCR 1716) at 139, safe and secure facility (CCR 1714(b)) at 33, misuse of education (BPC 4306.5) at 24, compounding limitations (CCR 1735.2) at 24. For technicians the list is dominated by self-administration of drugs or alcohol at 91 and conviction of a substantially related crime at 88.
• Also in this issue. The monkeypox waiver for prescriber dispensing of tecovirimat, the basic life support certification required to immunize under BPC 4052.8, checking whether a prescriber’s controlled substance authority is restricted before dispensing, diabetes test strip dealers reporting to the Board, scam calls aimed at DEA numbers and distributor account information, and the Strategic Plan 2022-2026.

Read the August 2022 issue on the Board’s website → (PDF, 39 pages)

March 2022

The 2022 new-laws issue, and the first appearance of two things that matter now: the elevated fine authority the Board uses against chains, and the standard of care conversation that eventually became AB 1503.

• Fines up to $100,000, and $150,000 where a policy caused it. AB 1533 added BPC 4317.5, authorizing fines up to $100,000 for repeated violations within five years by three or more community chain pharmacies under common ownership, and up to $150,000 where the violation resulted from a written policy or was expressly encouraged by the owner or manager. There is an opportunity to cure where no consumer was actually harmed.
• The Board’s own sunset extension, and a compounding seat. AB 1533 extended the Board’s operations to January 1, 2026 and changed the allocation of pharmacist members to include a representative of compounding pharmacies. It also expanded collaborative practice authority under BPC 4052(a)(13), added medication-assisted treatment under a state protocol, and extended advanced practice pharmacist authority beyond health care facilities.
• Compounding practice has to be reported at renewal. BPC 4110 and 4126.10 require a pharmacy to notify the Board about its compounding practices as part of the license renewal application.
• Independent vaccine initiation for patients three and older. AB 1064 authorized pharmacists to independently initiate and administer any FDA-approved or authorized vaccine with an ACIP recommendation for persons three years of age and older.
• E-prescribing became mandatory. The mandate under BPC 688 took effect January 1, 2022. Pharmacists may still dispense from legally written, oral or faxed prescriptions in the situations the law allows, and the Board published FAQs.
• A pharmacist in charge apologizes in public. A required apology letter from a PIC disciplined over dereliction of duties, published alongside the Board’s reminder that owners are expected to give the PIC adequate authority and that the PIC must actually exercise it. The Board cites the Sternberg decision, its precedential decision on PIC responsibility.
• Staffing and consultation in a vaccination program. The Board reminded licensees that pharmacists and not technicians provide the consultation, that pharmacies should not refuse to vaccinate eligible patients or demand proof of being immunocompromised for a booster, and that improperly stored or expired vaccine should never be administered.
• Also in this issue. Drug diversion mitigation strategies, a new CURES data vendor, the ISMP alert on age-related COVID-19 vaccine mix-ups, the compounding policy statement on the proposed USP revisions, inspection preparation resources, new ad hoc committees on medication errors and workforce and on standard of care, and other 2022 laws including expedited partner therapy (SB 306) and cancer medication recycling (SB 310).

Read the March 2022 issue on the Board’s website → (PDF, 38 pages)